Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million.

The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256 million, t...